ReviewDiscover oncology2025
From cell lines to animal models: "plant- derived chemotherapeutics unlocking new frontiers against oral squamous cell carcinoma"-a comprehensive systematic review.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Anti-cancer effects of plant extracts in head and neck squamous cell carcinoma.Frontiers in pharmacology · 2026Review
- Silibinin Triggers Mitochondrial Apoptosis and Declines Clonogenic Potential in Detroit 562 Human Pharyngeal Carcinoma Cells.Medicina (Kaunas, Lithuania) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimDespite progress in traditional treatment methods, the overall survival rate for oral squamous cell carcinoma (OSCC) remains limited. Consequently, it is essential to investigate alternative therapeutic strategies to enhance patient outcomes. This review highlights the potential role of plant extracts as chemo preventive agents in oral cancer treatment.
methodsA systematic review was conducted following PRISMA guidelines, involving an extensive literature search from databases such as PubMed, Scopus, Embase, Web of science, Cochrane and CINAHL which included studies from 2010 to 2024 that explored the anticancer potential of medicinal plants for OSCC treatment. Data extraction focused on plant species, parts used, extract type, active components, dosage, and cancer cell lines or animal models used. Risk of bias was assessed using the OHAT tool for animal studies and the ROBINS-I tool for in vitro studies.
resultsA total of 12 in vitro and animal studies were included, examining plants such as Allium sativum (garlic), Crocus sativus (saffron), Curcuma longa (turmeric), Scutellariabaicalensis (Baikal skullcap), etc., These studies demonstrated that bioactive components like allicin, curcumin, and baicalin significantly inhibited OSCC cell proliferation and induced apoptosis. However, there was substantial variability in the dose concentrations required, ranging from 1 µg/mL for garlic extract to 50 mg/mL for saffron nanoparticles. The risk of bias assessment indicated that four studies had a moderate risk, while one had a low risk of bias, indicating methodological rigor.
conclusionPlant extracts such as Curcuma longa and Vitis vinifera present a promising, less toxic alternative for OSCC treatment, with the potential to be integrated into conventional chemotherapeutic regimens. While in-vitro and animal studies are encouraging, further clinical trials among humans are necessary to confirm their efficacy and safety in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.